IGC Pharma (IGC)
XASE:IGC
Want to see IGC full AI Analyst Report?
Top Page
IGC Pharma
(NYSE MKT:IGC)
Select Model
Select Model
Rating:44Neutral
Price Target:
$0.28
▼(-7.67% Downside)
Action:Reiterated
Date:06/09/26
The score is primarily constrained by weak financial performance (sharp revenue contraction, large losses, and ongoing cash burn with equity erosion). Technicals are neutral-to-bearish with negative MACD and price below key moving averages. Corporate financing events provide some liquidity support, but valuation remains challenged due to losses (negative P/E) and no indicated dividend.
Positive Factors
Low leverage / debt-free balance sheet
Having essentially zero reported debt in the trailing twelve months materially lowers fixed financial obligations and interest risk. Over the next several months this structural strength preserves financial flexibility to fund R&D or negotiate financing without immediate debt-service pressure, improving solvency resilience while clinical programs advance.
Negative Factors
Sharp revenue decline and negative margins
A dramatic revenue contraction combined with extremely negative operating and net margins signals the company is not generating scalable commercial economics. Over a multi-month horizon this structural profitability shortfall impedes reinvestment, heightens dilution risk, and makes sustaining R&D spending dependent on external capital or partnerships.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage / debt-free balance sheet
Having essentially zero reported debt in the trailing twelve months materially lowers fixed financial obligations and interest risk. Over the next several months this structural strength preserves financial flexibility to fund R&D or negotiate financing without immediate debt-service pressure, improving solvency resilience while clinical programs advance.
Read all positive factors
IGC Pharma (IGC) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$28.28M
Dividend YieldN/A
Average Volume (3M)715.71K
Price to Earnings (P/E)―
Beta (1Y)0.62
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees67
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding100,091,320
10 Day Avg. Volume826,885
30 Day Avg. Volume715,709
Financial Highlights & Ratios
PEG Ratio0.17
Price to Book (P/B)4.08
Price to Sales (P/S)21.08
P/FCF Ratio-4.09
Enterprise Value/Market Cap1.02
Enterprise Value/Revenue24.21
Enterprise Value/Gross Profit81.56
Enterprise Value/Ebitda-4.61
Forecast
1Y Price Target
$5.25Price Target Upside1650.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
IGC Pharma Business Overview & Revenue Model
Company Description
IGC Pharma, Inc. operates as a pharmaceutical firm, currently in the clinical development phase, dedicated to pioneering novel treatments for Alzheimer's, a debilitating condition. The company's pipeline includes two experimental drug candidates a...
How the Company Makes Money
null...
IGC Pharma Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
24
Negative
| Breakdown | Mar 2026 | Mar 2025 | Mar 2024 | Jun 2023 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 1.19M | 1.27M | 1.34M | 911.00K | 397.00K |
| Gross Profit | 352.00K | 619.00K | 733.00K | -158.00K | 194.00K |
| EBITDA | -6.22M | -6.66M | -12.36M | -10.85M | -14.37M |
| Net Income | -6.55M | -7.12M | -13.00M | -11.51M | -15.02M |
Balance Sheet | |||||
| Total Assets | 9.19M | 8.75M | 9.90M | 17.18M | 26.83M |
| Cash, Cash Equivalents and Short-Term Investments | 207.00K | 405.00K | 1.20M | 3.35M | 10.46M |
| Total Debt | 0.00 | 238.00K | 348.00K | 481.00K | 611.00K |
| Total Liabilities | 3.06M | 2.42M | 2.58M | 2.27M | 2.94M |
| Stockholders Equity | 6.12M | 6.33M | 7.32M | 14.91M | 23.89M |
Cash Flow | |||||
| Free Cash Flow | -6.11M | -5.28M | -5.71M | -7.67M | -8.23M |
| Operating Cash Flow | -5.94M | -4.79M | -5.20M | -7.05M | -7.46M |
| Investing Cash Flow | -192.00K | -442.00K | -317.00K | -235.00K | -742.00K |
| Financing Cash Flow | 5.93M | 4.45M | 3.52M | 100.00K | 4.14M |
IGC Pharma Technical Analysis
Negative
0.30
Price Trends
0.30
Negative
0.29
Negative
0.33
Negative
Market Momentum
>-0.01
Positive
42.08
Neutral
<0.01
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IGC, the sentiment is Negative. The current price of 0.3 is above the 20-day moving average (MA) of 0.29, below the 50-day MA of 0.30, and below the 200-day MA of 0.33, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 42.08 is Neutral, neither overbought nor oversold. The STOCH value of <0.01 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IGC.
IGC Pharma Risk Analysis
IGC Pharma disclosed 37 risk factors in its most recent earnings report. IGC Pharma reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
IGC Pharma Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $24.86M | -3.41 | -695.82% | ― | 7.13% | -8.85% | |
50 Neutral | $103.50M | -3.60 | -1136.50% | ― | 417.63% | 91.39% | |
46 Neutral | $42.29M | 0.83 | -560.64% | ― | -32.64% | 56.66% | |
44 Neutral | $28.28M | -4.10 | -94.51% | ― | ― | ― | |
40 Underperform | $24.28M | -0.86 | 280.42% | ― | 4.35% | 20.37% |
* Healthcare Sector Average
IGC
IGC Pharma
0.28
-0.02
-6.00%
PLUR
Pluri
2.25
-2.15
-48.86%
DYAI
Dyadic International
0.68
-0.26
-27.45%
VRCA
Verrica Pharmaceuticals
6.03
-0.21
-3.31%
ELUT
Elutia
0.96
-0.82
-46.29%
IGC Pharma Corporate Events
Business Operations and StrategyPrivate Placements and Financing
IGC Pharma Extends and Amends $12 Million Loan Facility
Positive
Jun 8, 2026
IGC Pharma, Inc. amended and extended its existing Master Loan and Security Agreement and General Banking Facility Letter with Taiwan-based O-Bank Co., Ltd. on June 5, 2026. The renewed facility maintains a maximum aggregate limit of $12,000,000 w...
Business Operations and StrategyPrivate Placements and Financing
IGC Pharma Secures New Promissory Note Financing Agreements
Positive
Apr 20, 2026
On April 10, 2026, IGC Pharma, Inc. entered into a securities purchase agreement with FirstFire Global Opportunities Fund and, on April 14, 2026, issued a $346,910 promissory note, including a $39,910 original issue discount, for $307,000 in proce...
Business Operations and Strategy
IGC Pharma Launches National Media Partnership to Boost Visibility
Positive
Mar 31, 2026
On March 30, 2026, IGC Pharma announced a 12-part strategic national media partnership with financial media platform New to The Street to bolster its investor relations and corporate communications. The collaboration aims to expand visibility amon...
Business Operations and StrategyPrivate Placements and Financing
IGC Pharma Secures New Debt Financing for Liquidity
Positive
Mar 12, 2026
On March 5, 2026, IGC Pharma, Inc. entered into a Securities Purchase Agreement with Vanquish Funding Group Inc., issuing a $353,050 promissory note, including a $46,050 original issue discount, for a purchase price of $307,000 maturing on Februar...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.